Pacira BioSciences, Inc. PCRX Business Segments — Changes in contingent consideration

Similar metrics at other companies

CERTReportable Segment — Change in contingent consideration

$7.23M+4,139%

RYANReporting Segment — Change in contingent consideration

$27.29M+294%

LUNRReportable Segment — Change in fair value of contingent consideration liabilities

$521K—

INSMReportable Segment — Change in fair value of contingent consideration

-$46.96M-357%

TWSTReportable Segment — Change In Fair Value Of Contingent Consideration And Indemnity Holdback

$0—

FOURReportable Segment — Revaluation of contingent liabilities

$0-100%

Other financials

Income statement

See full

Revenue$177.4M+5.0%

Gross profit$141.0M+4.7%

Operating income$6.9M+247%

Net income$2.9M-39.4%

EPS (diluted)$0.07-30.0%

Balance sheet

See full

Cash & equivalents$144.3M-49.1%

Total debt$411.2M+15.3%

Total equity$653.9M-18.1%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow$25.7M-27.6%

CapEx$2.7M-68.1%

Free cash flow$23.0M-14.7%

Valuation

See full

Market cap$958.91M-14.5%

Enterprise value$1.23B+2.6%

P/E186.6×—

P/S1.3×-0.3×

Profitability

See full

Gross margin79.3%+1.7pp

Operating margin3.3%—

Net margin0.7%—

FCF margin18.1%-4.6pp

Returns & leverage

See full

Return on equity0.7%—

Debt / equity0.6×+0.2×

Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s business segments — changes in contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s business segments — changes in contingent consideration?: Pacira BioSciences, Inc. (PCRX) reported business segments — changes in contingent consideration of -$2.28M in Q1 2026.
How has Pacira BioSciences, Inc.'s business segments — changes in contingent consideration changed year-over-year?: Pacira BioSciences, Inc.'s business segments — changes in contingent consideration increased by 14.9% year-over-year, from -$2.68M to -$2.28M.
What does business segments — changes in contingent consideration mean?: Reflects adjustments to the fair value of earn-out or milestone payment obligations related to past acquisitions within the segment. Changes in this metric indicate shifts in the expected achievement of performance targets or valuation assumptions for acquired businesses.